02.12.2010 • News

Merck Set to Buy Biotech Firm SmartCells

U.S. pharmaceutical company Merck & Co. is set to buy SmartCells Inc, a privately held biotechnology firm in the early stages of developing a new diabetes drug, the Wall Street Journal reported.

The deal for SmartCells would exceed $500 million if various milestones for development, regulatory approval and sales were met and could be announced as early as Thursday, a person familiar with the matter told the Journal.

A SmartCells deal would expand Merck's treatment offerings for diabetes. It already has two top-selling drugs for Type 2 diabetics in its portfolio.

Merck could not be reached for comment.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.